Quantcast
Home > Quotes > ADMS
ADMS

Adamas Pharmaceuticals, Inc. Common Stock (ADMS) Quote & Summary Data

$9.79
*  
0.24
2.51%
Get ADMS Alerts
*Delayed - data as of Dec. 12, 2018 10:28 ET  -  Find a broker to begin trading ADMS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ADMS Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 9.77 / $ 9.82
Today's High / Low
$ 9.85 / $ 9.66
Share Volume
34,164
50 Day Avg. Daily Volume
667,930
Previous Close
$ 9.55
52 Week High / Low
$ 44 / $ 9.03
Market Cap
267,614,868
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
34,164
50 Day Avg. Daily Volume:
667,930

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -5.10

Trading Range

The current last sale of $9.79 is 8.42% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 9.85 $ 44
 Low: $ 9.66 $ 9.03

Company Description (as filed with the SEC)

At Adamas Pharmaceuticals, Inc., we seek to redefine the treatment experience for patients suffering from chronic neurological diseases. Our vision is grand, our goal bold: to create and commercialize a new generation of medicines intended to lessen the burden of disease on patients, caregivers and society. With a new commercial medicine and robust pipeline of investigational programs focused on meaningfully differentiated treatment options for patients, we believe we are well on our way. Our therapeutic targets include a broad range of neurologic diseases, including Parkinson's disease, multiple sclerosis, epilepsy and Alzheimer's disease. Our treatment innovations stem from a deep scientific understanding of time-dependent biology-the deliberate mapping of disease patterns and drug activity-along with a goal to meaningfully increase the efficacy of known molecules without compromising tolerability.  ... More ...  


Risk Grade

Where does ADMS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 9.66
Open Date:
Dec. 12, 2018
Close Price:
$ 9.55
Close Date:
Dec. 11, 2018

Consensus Recommendation

Analyst Info